Zevra Completes Acquisition of Acer Therapeutics: Read More
Here
.
Zevra.com
Olpruva.com
Remain on Acertx.com
Skip to content
Product
Pipeline
OLPRUVA™ Investigational Lifecycle Opportunities
EDSIVO™ for vEDS
Patients & Physicians
Patient Advocacy
Publications
Maple Syrup Urine Disease (MSUD)
Vascular Ehlers-Danlos Syndrome (vEDS)
Expanded Access
Contact Us
About
Pipeline
Investor Relations
Publications
Contact Us
Investor FAQs
Analyst Coverage
Corporate Governance
Stock Information
Events & Presentations
About
Pipeline
Investor Relations
Publications
Contact Us
0000806085-08-000145
SEC Reports
QUICK
NAV
MENU
MENU
About
Acer Management
Board of Directors
Key Strategic Consultants
Scientific Advisory Board
Product
Pipeline
Careers
OLPRUVA™ Investigational Lifecycle Opportunities
EDSIVO™ for vEDS
Patients & Physicians
Patient Advocacy
Publications
Maple Syrup Urine Disease (MSUD)
Vascular Ehlers-Danlos Syndrome (vEDS)
Expanded Access
Investor Relations
Press Releases
Events & Presentations
SEC Filings
Analyst Coverage
Stock Information
Corporate Governance
Investor FAQs
Contact Us
We use cookies to ensure that we give you the best experience on our website. By using our site, you consent to cookies.
Learn more.
Ok
